International law firm McDermott Will & Emery has advised AQEMIA, a pioneering pharmatech company leveraging AI and quantum-inspired physics to accelerate drug discovery, in its multi-year research collaboration with Sanofi.
The collaboration aims at discovering small molecule drug candidates across several therapeutic areas.
AQEMIA will leverage its unique platform that combines deep physics with generative AI at scale to identify the right chemical molecules for therapeutic targets of interest to Sanofi.
As part of the agreement, AQEMIA will be eligible to potentially receive up to $140 million based on an upfront payment and the successful completion of research and development milestones on a number of specific therapeutic targets.
Sanofi will be solely responsible for wet lab research, development and commercialisation activities.
The McDermott team that advised AQEMIA was led by Paris partner Emmanuelle Trombe and included associate, Edouard Becker.
